---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-379343"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-09-02T11:22:04+00:00"
generated_at: "2026-09-02T11:25:15.210703+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TScan cuts 75% of workforce, pauses Phase 3 ALLOHA-2, refocuses on in vivo solid tumors

## Summary
- Workforce reduction ~75%; ~$4.1M employee-related costs; $55.0M cumulative savings through 2027; cash runway into Q4 2027.
- Pauses Phase 3 ALLOHA-2 enrollment of TSC-101; 7 patients on treatment arm; 13/13 Cohort C patients show complete donor chimerism.
- CFO Jason Amello and CMO Chrystal Louis terminated; CEO Gavin MacBeath assumes principal financial/accounting officer duties.
- Nasdaq minimum bid price deficiency notice Aug 27, 2026; must regain $1.00 compliance by Feb 23, 2027.
- Two in vivo TCR-T candidates (PRAME, MAGE-A4) advance to IND-enabling; IND Q3 2027, Phase 1 Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-379343
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-09-02T11:22:04+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 3.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-379343
- JSON: https://secwatch.observer/filing/0001193125-26-379343.json
- Plain text: https://secwatch.observer/filing/0001193125-26-379343.txt

## Key facts
- Executive change
  Jason A. Amello was terminated as Chief Financial Officer at TScan Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
- Executive change
  Chrystal Louis was terminated as Chief Medical Officer at TScan Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
- Executive change
  Gavin MacBeath was appointed as Principal Financial Officer and Principal Accounting Officer at TScan Therapeutics, Inc..
  - Action: assumed
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: As of the Effective Date, Gavin MacBeath, Ph.D., the Company’s Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.